5 Results for "

RAF RBD

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "RAF RBD" in MCE Product Catalog:

  • Targets Recommended:
4
4 Cited Publications
Cat. No.: HY-15716
CAS No.: 436133-68-5
Purity:  99.93%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46±13 μM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15717
CAS No.: 454453-49-7
Purity:  98.20%
Target:  

Ras

Research Areas:  

Cancer

Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity .
loading...
    loading...
Cat. No.: HY-175870A
CAS No.: 3024878-21-2
Target:  

Ras ERK

Research Areas:  

Cancer

(7R)-Eras-4001 is an orally active KRAS mutant inhibitor with remarkable selectivity for H-RAS and N-RAS. (7R)-Eras-4001 effectively suppresses cancer cell viability by blocking downstream signaling pathways mediated by RAF family proteins, inhibiting the formation of the KRAS G12D-RAF1 RBD complex and the phosphorylation of ERK1/2. (7R)-Eras-4001 induces tumor growth inhibition and regression in a dose-dependent manner, and also reduces plasma ERK1/2 phosphorylation levels. (7R)-Eras-4001 exerts a synergistic effect with anti-PD-1 Cetuximab (HY-P9905). (7R)-Eras-4001 can be used in research on non-small cell lung cancer, pancreatic cancer, colorectal cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-184892
CAS No.: 2953305-55-8
Target:  

Ras Raf PERK p38 MAPK Apoptosis

Research Areas:  

Cancer

RMC-8839 is an orally active selective RAS (ON) G13C inhibitor with a Ki value of 28.3 nM. RMC-8839 disrupts the interaction between KRAS G13C and RAF1 (RBD). RMC-8839 inhibits RAS-MAPK pathway signaling by reducing DUSP6 mRNA levels and pERK levels. RMC-8839 induces cytotoxicity, apoptosis (apoptosis) and antiproliferative effects in KRAS G13C-mutated cells. RMC-8839 induces tumor stasis or regression in mice. RMC-8839 can be used in research related to non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-181964
CAS No.: 3023465-19-9
Research Areas:  

Cancer

KRAS G12C-IN-77 is an orally active and selective KRAS G12C covalent dual-state inhibitor that binds with high affinity to both GDP-bound (inactive state) and GTP-bound (active state) KRAS G12C (IC50 = 133 nM). KRAS G12C-IN-77 rapidly inhibits ERK1/2 phosphorylation, induces the formation of covalent adducts with endogenous KRAS G12C, suppresses the expression of MAPK pathway genes, and inhibits the proliferation of KRAS G12C-mutant cells. KRAS G12C-IN-77 is applicable to research related to KRAS G12C-mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer .
loading...
    loading...